Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early postoperative temozolomide injection for newly diagnosed glioblastoma
ChiCTR2000030789Phase 4Recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Oct 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of temozolomide in glioblastoma (GBM), sponsored by The First Hospital of Jilin University. Primary endpoint: Overall survival. Started Oct 2019; status: recruiting.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2000030789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030789.